This two-part study will assess the safety and tolerability of single ascending oral doses of RO6806127 in a group of healthy male participants and investigate the effect of high fat and high caloric food on the relative bioavailability of a single oral dose of RO6806127 in a separate group of healthy male participants. The relationship between drug exposure and tolerability will be explored.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
DOUBLE
Enrollment
37
Unnamed facility
Marlton, New Jersey, United States
Incidence of adverse events
Time frame: Up to Day 21
Phamacokinetic profile of single-dose oral RO6806127 and its metabolites as appropriate, as assessed by concentrations over time in plasma and urine
Time frame: Up to Day 21
RO6806127 metabolite concentrations in selected plasma and urine samples
Time frame: Up to Day 21
Relative bioavailability (food effect): Area under the concentration-time curves [AUC]
Time frame: Up to Day 21
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.